Atlas Trials

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Clinical trial NCT04379739 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04379739
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2020-07-26
Primary completion
2022-06-29
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.